Skip to main content
PMC home page
Gut logoLink to Gut
. 1972 Jan;13(1):47–53. doi: 10.1136/gut.13.1.47

Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease

G Acocella, L Bonollo, M Garimoldi, M Mainardi, L T Tenconi, F B Nicolis
PMCID: PMC1411976  PMID: 5060669

Abstract

The possible existence of kinetic interactions between rifampicin and isoniazid and the effect of the concomitant presence of an impaired liver function were investigated in man.

In a first study normal healthy subjects and patients with chronic liver disease received, on three different occasions, a single dose of 600 mg rifampicin or isoniazid and of rifampicin and isoniazid associated in randomized sequences. The results have shown that in both groups the serum levels, half-life values, and urinary excretion of each drug given alone are not significantly different from those observed when the other drug is associated. Serum levels and half-life of rifampicin and isoniazid were significantly higher in patients with chronically impaired liver.

In a second study, rifampicin and isoniazid were given in combination at the same doses as in the first study over a period of one week. The results have shown a trend to decrease in the serum levels of rifampicin of the healthy subjects and a trend to increase in the patients with chronic liver disease on day 7 of treatment. In both groups a reduction in the half-life of rifampicin was also observed. No changes in serum isoniazid concentrations were observed between day 1 and day 7 in the healthy subjects, whereas a significant increase was observed in the patients. No significant changes in the half-life of isoniazid were observed.

Full text

PDF
51

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BOURGEOIS P., DUBOIS-VERLIERE T., LEDOUAREC J. C., GANDON [Comparative study of chemical and bacteriological methods of assay for isoniazid in the blood and urine]. Rev Tuberc Pneumol (Paris) 1960 Apr;24:503–515. [PubMed] [Google Scholar]
  2. Cohn H. D. Clinical studies with a new rifamycin derivative. J Clin Pharmacol J New Drugs. 1969 Mar-Apr;9(2):118–125. [PubMed] [Google Scholar]
  3. Furesz S., Scotti R., Pallanza R., Mapelli E. Rifampicin: a new rifamycin. 3. Absorption, distribution, and elimination in man. Arzneimittelforschung. 1967 May;17(5):534–537. [PubMed] [Google Scholar]
  4. GLASS F., GOSSOW H., MALLAH H. J. BEOBACHTUNGEN UND UNTERSUCHUNGEN UEBER DIE GEMEINSAME WIRKUNG VON ALKOHOL UND ISONICOTINSAEUREHYDRAZID. Arzneimittelforschung. 1964 Nov;14:1203–1208. [PubMed] [Google Scholar]
  5. Glass F., Mallach H. J. Tierexperimentelle Untersuchungen über die Alkoholwirkung nach längerer Belastung mit Isonicotinsäurehydrazid. Arzneimittelforschung. 1965 Sep;15(9):1069–1070. [PubMed] [Google Scholar]
  6. HUGHES H. B. On the metabolic fate of isoniazid. J Pharmacol Exp Ther. 1953 Dec;109(4):444–452. [PubMed] [Google Scholar]
  7. JENNE J. W. Studies of human patterns of isoniazid metabolism using an intravenous fall-off technique with a chemical method. Am Rev Respir Dis. 1960 Jan;81:1–8. doi: 10.1164/arrd.1960.81.1.1. [DOI] [PubMed] [Google Scholar]
  8. Jezequel A. M., Orlandi F., Tenconi L. T. Changes of the smooth endoplasmic reticulum induced by rifampicin in human and guinea-pig hepatocytes. Gut. 1971 Dec;12(12):984–987. doi: 10.1136/gut.12.12.984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. LESTER D. THE ACETYLATION OF ISONIAZID IN ALCOHOLICS. Q J Stud Alcohol. 1964 Sep;25:541–543. [PubMed] [Google Scholar]
  10. Levi A. J., Sherlock S., Walker D. Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet. 1968 Jun 15;1(7555):1275–1279. doi: 10.1016/s0140-6736(68)92292-7. [DOI] [PubMed] [Google Scholar]
  11. MAHER J. R., WHITNEY J. M., CHAMBERS J. S., STANONIS D. J. The quantitative determination of isoniazid and para-aminosalicylic acid in body fluids. Am Rev Tuberc. 1957 Nov;76(5):852–861. doi: 10.1164/artpd.1957.76.5.852. [DOI] [PubMed] [Google Scholar]
  12. MANZINI C., CENCIOTTI L., TURCHETTO E. L'acétylation de l'acide para-amino-benzoique dans l'homme comme nouvelle méthode pour explorer la fonction hépatique. Presse Med. 1957 Jul 10;65(55):1295–1295. [PubMed] [Google Scholar]
  13. MITCHELL R. S., BELL J. C. Clinical implications of isoniazid blood levels in pulmonary tuberculosis. N Engl J Med. 1957 Nov 28;257(22):1066–1070. doi: 10.1056/NEJM195711282572202. [DOI] [PubMed] [Google Scholar]
  14. Maggi N., Furesz S., Pallanza R., Pelizza G. Rifampicin desacetylation in the human organism. Arzneimittelforschung. 1969 Apr;19(4):651–654. [PubMed] [Google Scholar]
  15. Michot F., Bürgi M., Büttner J. Rimactan (Rifampizin) und Antikoagulantientherapie. Schweiz Med Wochenschr. 1970 Mar 28;100(13):583–584. [PubMed] [Google Scholar]
  16. Peters J. H., Miller K. S., Brown P. Studies on the metabolic basis for the genetically determined capacities for isoniazid inactivation in man. J Pharmacol Exp Ther. 1965 Nov;150(2):298–304. [PubMed] [Google Scholar]
  17. Scharer L., Smith J. P. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med. 1969 Dec;71(6):1113–1120. doi: 10.7326/0003-4819-71-6-1113. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES